Intravitreal ranibizumab for choroidal neovascularization secondary to choroidal nevus.
To describe a patient treated with ranibizumab for juxtafoveal choroidal neovascularization secondary to choroidal nevus. A 71-year-old man presented with juxtafoveal choroidal neovascularization secondary to choroidal nevus. Choroidal neovascularization was initially treated with a single intravitreal injection of ranibizumab. The treatment was successful and best-corrected visual acuity improved from 20/50 to 20/25 and remained stable during 7 months. A recurrence was observed 9 months after initial treatment. Ranibizumab seems to be an effective treatment for choroidal neovascularization secondary to choroidal nevus. However, late recurrence may occur.